ITRM
NSCIterum Therapeutics plc
Healthcare•Biotechnology
Watchlists:
Last updated: Wednesday 9th July 2025
0.93
+0.01 (1.01%)
Prev Close:0.9237
Open:0.932
Bid:0.92
Ask:0.93
52 Week Range
0.813.02
Volume:524,714
Mkt Cap:39 M
26
MarketXLS Rank ®
Weak Hold
Price Target
$1.07
+14.7%
Financials
Financial Statements
ITRM - Cash Flow (Annual)
| Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Invalid date | |
|---|---|---|---|---|---|---|---|---|
| Capital Expenditure Reported | 2000.0 | 13000.0 | 62000.0 | 61000.0 | 11000.0 | 24000.0 | 90000.0 | |
| Cash Flow From Continuing Investing Activities | 18 M | 23 M | 14 M | -55 M | -11000.0 | 40 M | -9 M | |
| Change In Account Payable | -5 M | 2 M | 2 M | 63000.0 | -15 M | 11 M | 849000.0 | |
| Change In Accrued Expense | -5 M | 3 M | 3 M | -662000.0 | -11 M | 6 M | 3 M | |
| Change In Income Tax Payable | 155000.0 | 271000.0 | -510000.0 | 271000.0 | -120000.0 | 123000.0 | 120000.0 | |
| Change In Payables And Accrued Expense | -10 M | 6 M | 5 M | -328000.0 | -25 M | 17 M | 4 M | |
| Change In Prepaid Assets | -3 M | -3 M | -2 M | 1 M | 2 M | 2 M | -4 M | |
| Change In Tax Payable | 155000.0 | 271000.0 | -510000.0 | 271000.0 | -120000.0 | 123000.0 | 120000.0 | |
| Change In Working Capital | -13 M | 3 M | 2 M | -440000.0 | -25 M | 18 M | -2 M | |
| Depreciation And Amortization | 2 M | 3 M | 2 M | 2 M | 161000.0 | 514000.0 | 496000.0 | |
| Financing Cash Flow | 27 M | 1 M | -2 M | 83 M | 64 M | 2 M | 153 M | |
| Gain Loss On Investment Securities | -125000.0 | -423000.0 | ||||||
| Income Tax Paid Supplemental Data | 435000.0 | 120000.0 | 414000.0 | 352000.0 | ||||
| Interest Paid Supplemental Data | 416000.0 | 996000.0 | 1 M | 809000.0 | ||||
| Issuance Of Capital Stock | 90 M | 25 M | 3 M | 74 M | ||||
| Issuance Of Debt | -7 M | -5 M | -1 M | 15 M | ||||
| Net Common Stock Issuance | 90 M | 25 M | 3 M | 74 M | ||||
| Net Investment Properties Purchase And Sale | -12 M | -41 M | -46 M | -55 M | 40 M | -9 M | ||
| Net Investment Purchase And Sale | -12 M | -41 M | -46 M | -55 M | 40 M | -9 M | ||
| Net Issuance Payments Of Debt | -7 M | -5 M | -1 M | 15 M | ||||
| Net Long Term Debt Issuance | -7 M | -5 M | -1 M | |||||
| Net PPE Purchase And Sale | -2000.0 | -13000.0 | -62000.0 | -61000.0 | -11000.0 | -24000.0 | -90000.0 | |
| Net Preferred Stock Issuance | 64 M | |||||||
| Other Non-cash Items | 7 M | -8 M | 19 M | 68 M | 8 M | 3 M | 3 M | |
| Preferred Stock Issuance | 64 M | |||||||
| Proceeds From Stock Option Exercised | 60000.0 | 7000.0 | ||||||
| Purchase Of Investment | -12 M | -41 M | -46 M | -67 M | -96 M | |||
| Purchase Of PPE | -2000.0 | -13000.0 | -62000.0 | -61000.0 | -11000.0 | -24000.0 | -90000.0 | |
| Repayment Of Debt | -7 M | -6 M | -1 M | |||||
| Sale Of Investment | 13 M | 40 M | 88 M | |||||
| Stock Based Compensation | 363000.0 | 784000.0 | 5 M | 4 M | 3 M | 2 M | 3 M | |
| Unrealized Gain Loss On Investment Securities | 3 M | -11 M | -5 M | 61 M | 2 M | |||
| Amord | 2 M | 3 M | 4 M | 2 M | 11 M | 362000.0 | 360000.0 | |
| Begcash | 15 M | 5 M | 45 M | 8 M | ||||
| Capex | -2000.0 | -13000.0 | -62000.0 | -61000.0 | -11000.0 | -24000.0 | -90000.0 | |
| Cffcf | 27 M | 1 M | -2 M | 83 M | 64 M | 2 M | 153 M | |
| Cffinv | 18 M | 23 M | 14 M | -55 M | -11000.0 | 40 M | -9 M | |
| Cffoa | -27 M | -39 M | -18 M | -17 M | -58 M | -82 M | -76 M | |
| Chgcash | 18 M | -15 M | -6 M | 13 M | 10 M | -40 M | 68 M | |
| Chgothca | -2 M | |||||||
| Chgothcl | -385000.0 | -354000.0 | -708000.0 | -1 M | -1 M | -826000.0 | 242000.0 | |
| Chgothwc | 17000.0 | 795000.0 | -8000.0 | 308000.0 | -1 M | |||
| Chgpay | -5 M | 2 M | 1 M | 334000.0 | -15 M | 12 M | 969000.0 | |
| Comstkiss | 90 M | 25 M | 3 M | 74 M | ||||
| Depamor | 30000.0 | 31000.0 | 84000.0 | 7 M | 161000.0 | 152000.0 | 136000.0 | |
| Effexch | 4000.0 | -11000.0 | -22000.0 | -108000.0 | ||||
| Endcash | -40 M | -81 M | -65 M | 28 M | 15 M | 5 M | 77 M | |
| Fcf | -27 M | -39 M | -19 M | -16 M | -55 M | -82 M | -76 M | |
| Ltdebtiss | 744000.0 | |||||||
| Ltdebtpay | -7 M | -6 M | -1 M | |||||
| Netinccont | -25 M | -38 M | -44 M | -92 M | -52 M | -103 M | -77 M | |
| Netothfin | 45 M | |||||||
| Opcf | -27 M | -39 M | -18 M | -16 M | -55 M | -82 M | -76 M | |
| Opgainloss | -340000.0 | -125000.0 | -423000.0 | |||||
| Purchsti | -12 M | -41 M | -46 M | -67 M | -96 M | |||
| Salesti | 13 M | 40 M | 88 M |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement "your own" investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS provides all the tools I need for in-depth stock analysis. It's user-friendly and constantly improving. A must-have for serious investors.
I have been using MarketXLS for the last 6+ years and they really enhanced the product every year and now in the journey of bringing in AI...
MarketXLS is a powerful tool for financial modeling. It integrates seamlessly with Excel and provides real-time data.
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel.